No Detail Found!

Effects of telmisartan on paroxysmal atrial fibrillation in hypertensive patients

Author(s)
Jing Li Department of Cardiology, Tianyou Hospital, Affiliated to Wuhan University of Science and Technology,Wuhan, Hubei,China
Hangxiang Chen Department of Medicine, Wuhan Polytechnic University,Wuhan, Hubei,China
Qi Zhou Department of Cardiology, Tianyou Hospital, Affiliated to Wuhan University of Science and Technology,Wuhan, Hubei,China
Liangkun Hu Department of Cardiology, Tianyou Hospital, Affiliated to Wuhan University of Science and Technology,Wuhan, Hubei,China
Li Ma Department of Cardiology, Tianyou Hospital, Affiliated to Wuhan University of Science and Technology,Wuhan, Hubei,China
Hongyan Han Department of Cardiology, Tianyou Hospital, Affiliated to Wuhan University of Science and Technology,Wuhan, Hubei,China
Wei Li Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan, Hubei,China
Rong Du Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan, Hubei,China
Li Tian Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan, Hubei,China
Abstract
This study examined the effects and mechanisms of telmisartan in hypertensive patients with paroxysmal atrial fibrillation (PAF). Hypertensive patients with PAF (n=120) were randomized into test (telmisartan) and control (amlodipine besilate) groups. The pretreatment and post treatment left atrial dimension (LAD), high-sensitivity Creactive protein (hs-CRP) levels, heart rate, blood pressure (BP), and recurrence times of atrial fibrillation (AF) were recorded. The pretreatment and post treatment heart rates and BPs did not differ in either group (P>0.05). The post treatment systolic BP (SBP) and diastolic BP (DBP) did not differ between the groups (SBP: test, 132±5mmHg; control, 133±6 mmHg; DBP: test, 82±4 mmHg; control, 83±4mmHg). The LAD (test, 36.7±5.1 mm; control, 31.3±4.1mm) and hs-CRP (test, 5.6±2.6mg/L; control, 3.1±1.9mg/L) levels declined significantly (P>0.05) after treatment in the telmisartan group but not in the control group. After treatment, the LAD (test, 31.3±4.1mm; control, 36.2±4.6mm), hsCRP (test, 3.1±1.9 mg/L; control, 5.2±2.3mg/L) levels, and AF recurrence times were markedly lower in the test group (22) compared with the control group (44). Thus, telmisartan reduced the AF recurrence rates, LAD, and hs-CRP levels.
Publication Details
Page(s) 1651-1655
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 30, Issue: 5, Year: 2017

Request the full text from PASTIC

Keywords
Hypertension, paroxysmal atrial fibrillation, Telmisartan
0

Citations

0

Downloads

69

Views